¼¼°è ¿ø³» °¨¿° Ä¡·á ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø Áö¿ª Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® - º¸°í¼­ ¹üÀ§ : ¾àǰ Ŭ·¡½ºº°, °¨¿° À¯Çüº°, À¯Åë ä³Îº°, Áö¿ªº°
Hospital Acquired Infection Treatment Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Class, Infection Type, Distribution Channel, and Geography
»óǰÄÚµå : 1419132
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2023³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 171 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,450 £Ü 6,438,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 6,450 £Ü 9,332,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,450 £Ü 12,226,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ¿ø³» °¨¿° Ä¡·á ½ÃÀåÀº 2022³â 150¾ï 9,900¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 199¾ï 7,800¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2022-2030³â°£ CAGRÀº 3.6%·Î ÃßÁ¤µË´Ï´Ù.

½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ¿ø³» °¨¿°(HAI)ÀÇ ³ôÀº À¯Çà·ü, ȯÀÚÀÇ ¾ÈÀü¼º°ú °íǰÁú ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. ±×·¯³ª Ç×±ÕÁ¦ ³»¼º À§ÇùÀÌ ½ÃÀå ¼ºÀåÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù.

¿ø³» °¨¿° Ä¡·á ½ÃÀå ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

Áß¾Ó Á¤¸Æ ¶óÀÎ °ü·Ã Ç÷·ù °¨¿°, Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°, Àΰø È£Èí±â °ü·Ã Æó·Å µîÀº °Ç°­ °ü·Ã °¨¿°(HAI)ÀÇ ¿¹ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ °¨¿°Àº ¼ö¼ú ºÎÀ§¿¡¼­ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. 2021³â ¹ßÇ¥µÈ ¹Ì±¹ Áúº´¿¹¹æ°ü¸®¼¾ÅÍ(CDC)ÀÇ º¸°í¼­ ¡°2020³â Àü±¹ ¹× ÁÖÀÇ·á°ü·Ã °¨¿°Áõ °æ°úº¸°í¡±¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â 2019³âºÎÅÍ 2020³â¿¡ °ÉÃÄ Áß½ÉÁ¤¸Æ¶óÀÎ °ü·Ã Ç÷·ù °¨¿°Áõ, ¸ÞƼ½Ç¸° ³»¼º Ȳ»öÆ÷µµ»ó±¸±Õ(MRSA) ±ÕÇ÷Áõ, ÀΰøÈ£Èí±â °ü·Ã »ç°ÇÀÇ Áõ·Ê°¡ °¢°¢ 24%, 35%, 15% Áõ°¡Çß½À´Ï´Ù.

¶ÇÇÑ, 2022³â 1¿ù ¹Ì±¹ ÇコÄÉ¾î ¾ÈÀü ³×Æ®¿öÅ©(NHSN)ÀÇ º¸°í¼­¿¡ µû¸£¸é ¿ä·Î °¨¿°(UTI)Àº ÀÇ·á °ü·Ã °¨¿°ÀÇ 5¹øÂ°·Î ¸¹½À´Ï´Ù. ¿ä·Î °¨¿°Àº ±Þ¼º±â ÀÇ·á¿¡¼­ ÀÔ¿ø ȯÀÚÀÇ 9.5% ÀÌ»óÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. Ä«Å×ÅÍ °ü·Ã ¿ä·Î °¨¿°(CAUTI)Àº ¹æ±¤¿¡¼­ ¼Òº¯À» ¹èÃâÇϱâÀ§ÇÑ ¿äµµ Ä«Å×ÅÍ·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. CAUTI´Â ÀÔ¿ø Áß ¿ä·Î °á¼® ȯÀÚ Áß °¡Àå ºó¹øÇÑ °¨¿° Áß ÇϳªÀÔ´Ï´Ù. ¹Ì±¹ Áúº´ ¿¹¹æ °ü¸® ¼¾ÅÍ(CDC)¿¡ µû¸£¸é °¨¿°ÀÇ °ÅÀÇ 75%°¡ ¿äµµ Ä«Å×ÅÍ¿Í °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ÀÔ¿ø Áß ÀÔ¿ø ȯÀÚÀÇ 15-25%´Â ¿äµµ Ä«Å×Å͸¦ »ç¿ëÇØ¾ß ÇÕ´Ï´Ù. ¿äµµ Ä«Å×ÅÍÀÇ Àå±â »ç¿ëÀº CAUTI¸¦ ÀÏÀ¸Å°´Â °¡Àå Å« À§Çè ¿ä¼ÒÀÔ´Ï´Ù. CAUTIÀÇ ÇÕº´ÁõÀº ȯÀÚÀÇ °íÅë, ÀÔ¿ø ±â°£ÀÇ ¿¬Àå, Ä¡·áºñ Áõ°¡, ½ÉÁö¾î »ç¸ÁÀ» ÃÊ·¡ÇÕ´Ï´Ù.

¿ø³» °¨¿° Ä¡·á ½ÃÀåÀÇ ±âȸ

Ç×»ýÁ¦, Ç×Áø±ÕÁ¦ ¹× Ç×¹ÙÀÌ·¯½ºÁ¦¸¦ Æ÷ÇÔÇÑ »õ·Î¿î Ç×±ÕÁ¦ÀÇ Áö¼ÓÀûÀÎ °³¹ßÀº HAI¿Í ½Î¿ì°í »õ·Î¿î ³»¼º ÆÐÅÏÀ» ´Ù·ç°í Ä¡·á ¿É¼ÇÀ» ³ÐÈú ¼öÀÖ´Â ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÀÇ·á±â°ü, Á¦¾à±â¾÷ ¹× ¿¬±¸±â°üÀÇ °øµ¿ ÀÌ´Ï¼ÅÆ¼ºê´Â »õ·Î¿î Ä¡·á Ç¥Àû ¹ß°ß, Ç×»ýÁ¦ ¹ß°ß, Â÷¼¼´ë °¨¿° Ä¡·á Àü·« °³¹ß ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

¿ø³» °¨¿° Ä¡·á ½ÃÀå ºÎ¹®º° °³¿ä

¿ø³» °¨¿° Ä¡·á ½ÃÀåÀº ¾à¹° Ŭ·¡½ºº°·Î Ç×±ÕÁ¦, Ç×¹ÙÀÌ·¯½ºÁ¦, Ç×Áø±ÕÁ¦ µîÀ¸·Î ±¸ºÐµË´Ï´Ù. Ç×±ÕÁ¦ ºÎ¹®Àº 2022³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϸç 2022-2030³â¿¡ °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿ø³» °¨¿° Ä¡·á ½ÃÀåÀº °¨¿° À¯Çüº°·Î ¿ä·Î °¨¿°, Àΰø È£Èí±â °ü·Ã Æó·Å, ¼ö¼ú ºÎÀ§ °¨¿°, Ç÷·ù °¨¿° ¹× ±âŸ ¿ø³» °¨¿°À¸·Î ±¸ºÐµË´Ï´Ù. ¿ä·Î °¨¿° ºÐ¾ß´Â 2022³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ±×·¯³ª ÀΰøÈ£Èí±â °ü·Ã Æó·Å ºÐ¾ß´Â 2022-2030³â°£ °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿ø³» °¨¿° Ä¡·á ½ÃÀåÀº À¯Åë ä³Îº°·Î º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ÀüÀÚ»ó°Å·¡ µîÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â¿¡´Â º´¿ø ¾à±¹ ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí 2022-2030³â¿¡´Â ÀÌ ºÎ¹®ÀÌ °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿ø³» °¨¿° Ä¡·á ½ÃÀå Áö¿ªº° °³¿ä

¾Æ½Ã¾ÆÅÂÆò¾çÀº 2022-2030³â°£ °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. Àεµ¿Í Áß±¹°ú °°Àº ¾Æ½Ã¾ÆÅÂÆò¾ç ±¹°¡µéÀº ¿ø³» °¨¿° Ä¡·á ½ÃÀå ¼ºÀåÀÇ Å« ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÇ·á ÀÎÇÁ¶óÀÇ °³¼±, ÀÇ·áºñ Áõ°¡, ÷´Ü ÀÇ·á ±â¼úÀÇ µµÀÔ¿¡ ´ëÇÑ ÁÖ¸ñÀÇ °íÁ¶µîÀ» ¹è°æÀ¸·Î, ÀÌ Áö¿ªÀÇ ½ÅÈï±¹Àº ½ÃÀå È®´ëÀÇ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

2022³â¿¡´Â ºÏ¹Ì°¡ ¼¼°è ¿ø³» °¨¿° Ä¡·á ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¹Ì±¹Àº HAIÀÇ À¯º´·üÀÌ ³ô¾Æ ¿ø³» °¨¿° Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. CDC¿¡ µû¸£¸é ¾î´À ³¯ º´¿ø ȯÀÚ Áß 31¸í Áß 1¸íÀÌ Àû¾îµµ ÇϳªÀÇ HAI¸¦ ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ¸¶Âù°¡Áö·Î Office of Disease Prevention and Health Promotion¿¡ µû¸£¸é HAI ¹× ±âŸ °¨¿°Àº ÆÐÇ÷ÁõÀ¸·Î À̾îÁú ¼ö ÀÖÀ¸¸ç ¹Ì±¹¿¡¼­´Â ¿¬°£ 170¸¸ ¸íÀÌ ¹ß»ýÇϰí 27¸¸ ¸íÀÌ »ç¸ÁÇϰí ÀÖ´Ù°í ÇÕ´Ï´Ù. µû¶ó¼­ ¹Ì±¹¿¡¼­´Â HAIÀÇ À¯º´·üÀÌ ³ô¾Æ ¿ø³» °¨¿° Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

°Ô´Ù°¡ US Centers for Medicare & Medicaid Services¿¡ µû¸£¸é ¹Ì±¹ÀÇ ±¹¹Î ÀÇ·áºñ´Â 2021³â 2.7% Áõ°¡ÇÏ¿© 4Á¶ 3,000¾ï ´Þ·¯, 1Àδç 1¸¸ 2,914 ´Þ·¯¿¡ À̸¨´Ï´Ù. ¶Ç ÀÇ·áºñ´Â ±¹³»ÃÑ»ý»êÀÇ 18.3%¸¦ Â÷ÁöÇÕ´Ï´Ù. °Ô´Ù°¡ US Department of Health & Human Services¿¡ µû¸£¸é ±¹¹ÎÀÇ·áÁöÃâÀº 2019³âºÎÅÍ 2028³â±îÁö ¿¬·ü 5.4%·Î ¼ºÀåÇÏ¿© 2028³â¿¡´Â 6Á¶ 2,000¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÇ·á ÁöÃâ Áõ°¡´Â HAI Ä¡·áÁ¦ °³¹ß°ú °ü·ÃµÈ ¿¬±¸¿¡¼­ ´Ù¾çÇÑ ÀڱݿøÀ» Áõ°¡½ÃŰ°í ¿ø³» °¨¿° Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ºÎÃß±æ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

¿ø³» °¨¿° Ä¡·á ½ÃÀå¿¡ °üÇÑ º¸°í¼­ ÀÛ¼º½Ã ÂüÁ¶ÇÑ ÁÖ¿ä 1Â÷ Á¤º¸ ¹× 2Â÷ Á¤º¸¿¡´Â ¼¼°èÀºÇà µ¥ÀÌÅÍ, ±¹¹Îº¸°Ç¼­ºñ½º(NHS), FDA(½ÄǰÀǾàǰ±¹), EMA(À¯·´ÀǾàǰû), WHO(¼¼°èº¸°Ç ±â°ü) µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¿ø³» °¨¿° Ä¡·á ½ÃÀå »óȲ

Á¦5Àå ¿ø³» °¨¿° Ä¡·á ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ

Á¦6Àå ¿ø³» °¨¿° Ä¡·á ½ÃÀå : ¼¼°è ½ÃÀå ºÐ¼®

Á¦7Àå ¿ø³» °¨¿° Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº° ¼öÀÍ ºÐ¼®(2020-2030³â)

Á¦8Àå ¿ø³» °¨¿° Ä¡·á ½ÃÀå : °¨¿° À¯Çüº° ¼öÀÍ ºÐ¼®(2020-2030³â)

Á¦9Àå ¿ø³» °¨¿° Ä¡·á ½ÃÀå : À¯Åë ä³Îº° ¼öÀÍ ºÐ¼®(2020-2030³â)

Á¦10Àå ¿ø³» °¨¿° Ä¡·á ½ÃÀå :Áö¿ªº° ¼öÀÍ ºÐ¼®(2020-2030³â)

Á¦11Àå ¾÷°è Á¤¼¼

Á¦12Àå °æÀï ±¸µµ

Á¦13Àå ¿ø³» °¨¿° Ä¡·á ½ÃÀå - ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦14Àå ºÎ·Ï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global hospital-acquired infection treatment market is expected to reach US$ 19.978 billion in 2030 from US$ 15.099 billion in 2022. The market is estimated to grow with a CAGR of 3.6% from 2022 to 2030.

The key factors driving the market's growth include the high prevalence of hospital-acquired infections (HAI) and the growing focus on patient safety and quality care. However, the threat of antimicrobial resistance hinders market growth.

Market Drivers of the Hospital-Acquired Infection Treatment Market

Central line-associated bloodstream infections, catheter-associated urinary tract infections, and ventilator-associated pneumonia are a few examples of healthcare-associated infections (HAIs). These infections can also arise at surgical sites. According to the Centers for Disease Control and Prevention (CDC) report "2020 National and State Healthcare-Associated Infections Progress Report" published in 2021, cases of central line-associated bloodstream infections, Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, and ventilator-associated events increased by 24%, 35%, and 15%, respectively, in the US between 2019 and 2020.

Furthermore, According to the January 2022 report from the National Healthcare Safety Network (NHSN), urinary tract infections (UTIs) are the fifth most common type of healthcare-associated infection. UTIs account for more than 9.5% of acute care hospital conditions. Catheter-associated urinary Tract Infection (CAUTI) is caused by urinary catheters used to drain urine from the bladder. CAUTI is one of the most frequent infections among hospitalized UTI patients. According to the Centers for Disease Control and Prevention (CDC), nearly 75% of infections are related to a urinary catheter. During hospital stays, 15% to 25% of hospitalized patients must use urinary catheters. Prolonged urinary catheter use is the most major risk factor for getting CAUTI. CAUTI complications entail patient suffering, prolonged hospital stays, increased treatment costs, and even death.

Opportunities in the Hospital-Acquired Infection Treatment Market

The continuous development of novel antimicrobial agents, including antibiotics, antifungals, and antivirals, presents opportunities for combating HAIs, addressing emerging resistance patterns, and expanding the armamentarium of treatment options. Additionally, collaborative initiatives among healthcare institutions, pharmaceutical companies, and research organizations present opportunities for discovering novel therapeutic targets, discovering antibiotics, and developing next-generation infection treatment strategies.

Hospital Acquired Infection Treatment Market: Segmental Overview

The hospital acquired infection treatment market, by drug class, is segmented into antibacterial, antiviral, antifungal, and others. The antibacterial drugs segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022-2030.

The hospital acquired infection treatment market, by infection type, is segmented into urinary tract infections, ventilator-associated pneumonia, surgical site infections, bloodstream infections, and other hospital infections. The urinary tract infections segment held the largest market share in 2022. However, the ventilator-associated pneumonia segment is anticipated to register the highest CAGR from 2022 to 2030.

The hospital acquired infection treatment market, by distribution channel, is segmented into hospital pharmacies, retail pharmacies, e-commerce, and others. In 2022, the hospital pharmacies segment held the largest market share, and the same segment is anticipated to register the highest CAGR during 2022-2030.

Hospital Acquired Infection Treatment Market: Geographical Overview

Asia Pacific is estimated to register the highest CAGR from 2022 to 2030. Countries in the Asia Pacific, such as India and China, hold significant potential for the hospital-acquired infection treatment market growth. Developing countries in the region with improving healthcare infrastructure, increasing healthcare expenditure, and a rising focus on adopting advanced medical technologies offer opportunities for market expansion.

In 2022, North America held the largest share of the global hospital-acquired infection treatment market. The US has a high prevalence of HAI, which propels the hospital-acquired infection treatment market growth. As per the CDC, on any given day, about 1 in 31 hospital patients has at least one HAI. Similarly, according to the Office of Disease Prevention and Health Promotion, HAIs and other infections can lead to sepsis, and it causes 1.7 million illness cases and 270,000 deaths per year in the US. Thus, the high prevalence of HAI among people in the US fuels the hospital-acquired infection treatment market growth.

Furthermore, according to the US Centers for Medicare & Medicaid Services, national healthcare expenditures in the US will increase by 2.7 percent in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Also, health spending accounted for 18.3 percent of the nation's Gross Domestic Product. Furthermore, according to the US Department of Health & Human Services, National health spending is expected to grow at a 5.4% annual rate from 2019 to 2028, and it is expected to reach US$ 6.2 trillion by 2028. The rising health expenditure is estimated to increase various funding sources in the research related to the development of HAI drugs, fueling the demand for hospital-acquired infection treatment.

A few of the major primary and secondary sources referred to while preparing the report on the hospital-acquired infection treatment market are the World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization).

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Hospital Acquired Infection Treatment Market Landscape

5. Hospital Acquired Infection Treatment Market - Key Market Dynamics

6. Hospital Acquired Infection Treatment Market - Global Market Analysis

7. Hospital Acquired Infection Treatment Market - Revenue Analysis (USD Million) - By Drug Class, 2020-2030

8. Hospital Acquired Infection Treatment Market - Revenue Analysis (USD Million) - By Infection Type, 2020-2030

9. Hospital Acquired Infection Treatment Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

10. Hospital Acquired Infection Treatment Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

Note - Similar analysis would be provided for below mentioned regions/countries

11. Industry Landscape

12. Competitive Landscape

13. Hospital Acquired Infection Treatment Market - Key Company Profiles

Note - Similar information would be provided for below list of companies

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â